Pet IFN-γ Therapeutic Antibody Development
Creative Biolabs provides specialized therapeutic antibody development services designed for the veterinary field, with a focus on advancing canine and feline health. Our dedicated platforms and services are built to accelerate antibody discovery, engineering, and preclinical validation against high-value immunological targets such as interferon gamma (IFN-γ). With a track record in translational biology and veterinary biotechnology, we support pharmaceutical and biotech partners seeking novel solutions to chronic and immune-mediated diseases in pets. If your team is evaluating IFN-γ as a target for therapeutic development, we invite you to connect with us to explore tailored strategies.
Platforms in Therapeutic Antibody Discovery
We offer a broad suite of R&D platforms designed for robust antibody discovery and optimization. For development teams seeking a discovery partner, Creative Biolabs ensures access to multiple discovery engines that can be aligned with your program goals.
- Phage Display: Our proprietary canine and feline phage display libraries allow rapid screening and enrichment of diverse antibody candidates with high affinity and specificity against IFN-γ. This platform accelerates identification of lead molecules with therapeutic potential in veterinary immunology.
- Single-B Cell Sorting: By isolating murine B cells producing IFN-γ-specific antibodies, we generate natural monoclonal candidates that can be engineered and optimized for use in canine and feline systems. This strategy ensures high diversity while maintaining functional relevance.
- Hybridoma Technology: Hybridoma-based discovery remains a powerful method for generating reliable antibody candidates, which are then engineered to meet veterinary species requirements. Our hybridoma workflows seamlessly integrate with downstream engineering for therapeutic applications.
Comprehensive Antibody Development Services
Our services extend across the entire development pipeline, ensuring that IFN-γ antibodies for pets progress from concept to preclinical evaluation with confidence. If your pipeline requires a partner with experience in veterinary-specific antibody optimization and evaluation, contact Creative Biolabs to discuss how our services can align with your project.
Antibody Characterization
We provide detailed binding, specificity, and stability analyses to confirm lead candidate performance under relevant biological conditions.
Antibody Engineering
Our expertise in Fc engineering, species adaptation, and human-to-pet reformatting ensures optimized safety, immunogenicity, and efficacy in companion animals.
Preclinical Evaluation
With both in vitro assays and in vivo veterinary models, we deliver reliable preclinical data to support decision-making on therapeutic readiness.
Antibody Development
From lead selection to scale-up-ready constructs, we provide end-to-end support to accelerate candidates into translational research.
Why Focus on IFN-γ?
Interferon gamma (IFN-γ) is a pro-inflammatory cytokine central to host defense and immune regulation. In canine and feline medicine, excessive or dysregulated IFN-γ activity is linked to a spectrum of chronic and autoimmune disorders. In dogs, it has been implicated in conditions such as atopic dermatitis, inflammatory bowel disease, and certain autoimmune neuropathies. In cats, IFN-γ dysregulation is associated with chronic viral infections, inflammatory respiratory disease, and immune-mediated tissue damage. Given its role as a master regulator of inflammation, IFN-γ represents a critical therapeutic target for both species, enabling antibody-based therapies that can restore balance in immune signaling.
Mechanism of Action
Antibodies directed against IFN-γ act by binding to the cytokine and preventing its interaction with IFN-γ receptors on immune cells. This blockade dampens the downstream signaling cascade that drives excessive macrophage activation, T cell proliferation, and release of secondary pro-inflammatory mediators. By selectively modulating IFN-γ activity, therapeutic antibodies provide a targeted approach to reducing chronic inflammation without broadly suppressing the immune system. This precise mechanism makes anti-IFN-γ antibodies promising candidates for managing immune-mediated diseases in pets while preserving host defense against infections.
Fig 1. Inhibition of accumulation of Ly6C high macrophages in lamina propria by administering IFN-γ primed cAMSCs.1
Our Advantages
Partner with Creative Biolabs
The demand for innovative immunotherapies in veterinary medicine continues to rise, and IFN-γ antibodies stand out as high-impact candidates for canine and feline care. Creative Biolabs is committed to accelerating the path from target validation to therapeutic readiness, offering a complete ecosystem of discovery and development support. Whether you are a biotech exploring new pipelines or a pharmaceutical company advancing veterinary R&D, we welcome the opportunity to collaborate.
Contact us today to discuss your IFN-γ therapeutic antibody development goals and explore how Creative Biolabs can bring your program closer to clinical reality.
Reference
- Jo, Chan-Hee et al. "Regulation of Colonic Inflammation and Macrophage Homeostasis of IFN-γ-Primed Canine AMSCs in Experimental Colitis in Mice." Animals : an open access journal from MDPI vol. 14,22 3283. 14 Nov. 2024. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ani14223283